Pulse Biosciences (NASDAQ:PLSE) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research note published on Thursday morning.

Pulse Biosciences Stock Up 1.6 %

Shares of PLSE stock opened at $11.19 on Thursday. The firm has a market cap of $617.97 million, a price-to-earnings ratio of -13.81 and a beta of 1.76. Pulse Biosciences has a 12 month low of $3.78 and a 12 month high of $14.96. The stock has a 50-day moving average price of $10.06 and a 200 day moving average price of $9.55.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Tuesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter.

Insider Transactions at Pulse Biosciences

In related news, CEO Burke Thomas Barrett bought 10,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was bought at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the transaction, the chief executive officer now owns 10,000 shares of the company’s stock, valued at $85,600. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 71.50% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

A number of hedge funds have recently modified their holdings of PLSE. PNC Financial Services Group Inc. acquired a new stake in shares of Pulse Biosciences during the fourth quarter worth about $242,000. Griffin Asset Management Inc. raised its position in shares of Pulse Biosciences by 15.7% during the first quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock worth $2,616,000 after purchasing an additional 40,700 shares during the period. BNP Paribas Financial Markets raised its position in shares of Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares during the period. Inspire Investing LLC raised its position in shares of Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock worth $360,000 after purchasing an additional 10,039 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after purchasing an additional 189,227 shares during the period. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.